Clinical trial NCT00126581 (phase 2, status: completed)
Conditions: lung adenocarcinoma, lung adenosquamous carcinoma, malignant pericardial effusion, malignant pleural effusion, minimally invasive lung adenocarcinoma, stage iiib lung non-small cell cancer ajcc v7, stage iv lung non-small cell cancer ajcc v7
ICD codes: D02.20, D02.21, D02.22, C96.20, C96.29, D47.09, C96.20, C96.29, D47.09
Drugs: carboplatin, erlotinib, erlotinib hydrochloride, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic documentation of primary lung adenocarcinoma including any variant thereof
             such as pure or mixed bronchioloalveolar carcinoma or adenosquamous cell carcinoma;
             patients with non-small cell lung cancer (NSCLC) not otherwise specified (NOS) are not
             eligible

               -  Pathology block or unstained slides from initial or subsequent diagnosis must be
                  available for sequencing of EGFR, K-ras, Erb-2 and B-raf; patients need to have
                  had at least a core biopsy; patients whose diagnosis was made through a fine
                  needle aspirate will not have sufficient material for mutational analysis and are
                  not eligible

          -  Select stage IIIB with cytologically documented malignant pleural or pericardial
             effusion OR stage IV disease

          -  Patients must be chemotherapy naïve; they may not have received neo-adjuvant or
             adjuvant chemotherapy

          -  No prior exposure to OSI-774 (erlotinib) or other treatments targeting the human
             epidermal growth factor receptor (HER) family axis (e.g., trastuzumab, gefitinib,
             cetuximab, lapatinib, etc.)

          -  No uncontrolled central nervous system metastases (i.e., any known central nervous
             system [CNS] lesion which is radiographically unstable, symptomatic and/or requiring
             corticosteroids); patients must be >= 3 weeks beyond completing cranial irradiation
             and off corticosteroid therapy

          -  >= 3 weeks since prior radiation therapy

          -  >= 3 weeks since prior major surgery

          -  No treatment with an investigational agent currently or within the last 28 days

          -  Non-smoker or former light smoker; non-smoker is defined as a person who smoked =< 100
             cigarettes in their lifetime while a former light smoker is a patient who smoked
             between > 100 cigarettes AND =< 10 pack years AND quit >= 1 year ago; this must be
             documented on the On-study Form (C-1405)

          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1

          -  Non-pregnant and non-nursing

          -  No dysphagia or active gastrointestinal disease or disorder that alters
             gastrointestinal motility or absorption; no lack of integrity of the gastrointestinal
             tract (e.g., a significant surgical resection of the stomach or small bowel); patients
             unable to swallow intact tablets must be able to swallow tablets dissolved in water

          -  Measurable disease is defined as at least one lesion that can be accurately measured
             in at least one dimension (longest diameter to be recorded) as >= 20 mm with
             conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan;
             lesions that are considered non-measurable include the following:

               -  Bone lesions

               -  Leptomeningeal disease

               -  Ascites

               -  Pleural/pericardial effusion

               -  Lymphangitis cutis/pulmonis

               -  Abdominal masses that are not confirmed and followed by imaging techniques

               -  Cystic lesions

          -  Granulocyte >= 1,500/mcl

          -  Platelet count >= 100,000/mcl

          -  Hemoglobin >= 9.0 g/dL

          -  Total bilirubin =< upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =<
             2.5 x ULN

          -  Creatinine =< 1.5 mg/dl